Medication info
Seltanapin Tablets (Terbinafine Hydrochloride)

Seltanapin Tablets (Terbinafine Hydrochloride)

Prescription medicationTablet
Ingredient · strength
Terbinafine Hydrochloride›140.625mg / 1 tablet
Manufacturer / importer
NBK Pharmaceutical Co., Ltd.
Appearance
White to almost off-white circular tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201803943 · Approved 2018.10.08

Summary

Main use
Treatment of onychomycosis and cutaneous fungal infections (tinea pedis, tinea corporis, etc.), and tinea capitis
Who uses it
Adults · Children
Adult dosage
Administer terbinafine 125 mg per dose twice daily or 250 mg per dose once daily. The duration of administration by condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital or plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Usually administer for 6 weeks~3 months. For infections of the fingernails or relatively small toenails, or in younger patients, the treatment duration may be shortened to 3 months or less. A treatment period of 3 months is usually sufficient for toenail infections, but some patients may require 6 months or longer. Treatment may need to be longer in patients with slow nail growth. For patients with creatinine clearance below 50 mL/minute, reduce the daily dose by 1/2.
Children's dosage
Administer to children aged 2 years and older. Administration is not recommended for children under 2 years of age because there is no experience with use in this age group. Tinea capitis: 4 weeks 1) Body weight below 20 kg (under 5 years): Administer 62.5 mg per dose once daily. 2) Body weight 20~40 kg (5~12 years): Administer 125 mg per dose once daily. 3) Body weight over 40 kg (over 12 years): Administer 250 mg per dose once daily.

Ingredients

Manufacturer
NBK Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of onychomycosis and cutaneous fungal infections (tinea pedis, tinea corporis, etc.), and tinea capitis

  • Skin fungal infections
  • athlete's foot
  • body tinea
  • groin tinea
  • toenail and fingernail fungal infections
  • tinea capitis
View approved original text

This medication is effective for various skin fungal infections caused by dermatophytes, such as athlete's foot, body tinea, and groin tinea (jock itch). It is also used to treat adult toenail and fingernail fungal infections. In children, it is used for the treatment of tinea capitis. This medication helps improve various fungal infections of the skin and nails.

Dosage and Administration

Adult dosage

Administer terbinafine 125 mg per dose twice daily or 250 mg per dose once daily. The duration of administration by condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital or plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Usually administer for 6 weeks~3 months. For infections of the fingernails or relatively small toenails, or in younger patients, the treatment duration may be shortened to 3 months or less. A treatment period of 3 months is usually sufficient for toenail infections, but some patients may require 6 months or longer. Treatment may need to be longer in patients with slow nail growth. For patients with creatinine clearance below 50 mL/minute, reduce the daily dose by 1/2.

Children's dosage

Administer to children aged 2 years and older. Administration is not recommended for children under 2 years of age because there is no experience with use in this age group. Tinea capitis: 4 weeks 1) Body weight below 20 kg (under 5 years): Administer 62.5 mg per dose once daily. 2) Body weight 20~40 kg (5~12 years): Administer 125 mg per dose once daily. 3) Body weight over 40 kg (over 12 years): Administer 250 mg per dose once daily.

Precautions

This medication is not recommended for patients with chronic liver disease or active liver disease. Before taking the medication, liver function tests (AST/ALT) should be done, and liver function should be regularly monitored within 4-6 weeks after the start of treatment. If liver function test results increase, the medication should be stopped immediately, and if symptoms such as nausea, loss of appetite, fatigue, vomiting, abdominal pain, or jaundice occur, the doctor should be notified immediately. This medication can rarely cause serious liver damage such as hepatic failure, so if there are symptoms of liver dysfunction, administration should be stopped immediately and tests should be conducted. This medication should not be used in patients with blood disorders or severely impaired kidney function, children under 2 years of age, or breastfeeding women. Additionally, individuals allergic to this medication or its ingredients should not take it. If a rash or severe itching or serious skin reactions occur during administration, the medication should be stopped immediately and medical attention should be sought. This medication can cause musculoskeletal symptoms such as muscle pain or joint pain, and in rare cases, severe muscle damage may occur, so if symptoms are severe, it should be reported immediately. If dizziness, hypotension, or difficulty breathing occurs, the medication should also be discontinued immediately. This medication can cause gastrointestinal disturbances such as indigestion, nausea, and diarrhea, and has been reported to cause mental and neurological symptoms such as depression, headaches, and taste disturbances. Caution should be taken as dizziness may occur when driving or operating machinery. This medication may interact with other drugs, so if other medications are being taken, the doctor or pharmacist must be informed. Particularly when taken with medications metabolized in the liver, monitoring or dosage adjustments may be necessary. Women who are pregnant or may become pregnant should carefully weigh the benefits and risks of taking this medication, and nursing mothers should discontinue breastfeeding while taking it. Care should be taken in pediatric or elderly patients, as liver and kidney functions may be reduced. Overdose may result in headaches, nausea, abdominal pain, and dizziness, and appropriate treatment should be sought at a hospital immediately. This medication should be stored out of the reach of children and kept at room temperature away from direct sunlight.

Side effects

Liver and bile duct failure, hepatitis, bile duct obstruction, jaundice, rash, skin itching, fever, nausea, vomiting, loss of appetite, malaise, elevated γ-GTP, elevated AST/ALT, elevated LDH, elevated ALP, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, subcutaneous bleeding, leukopenia, anemia, rash, itching, photosensitivity reaction, mucocutaneous syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, blistering dermatitis, psoriatic rash, exacerbation of psoriasis, hair loss, musculoskeletal reactions, arthralgia, myalgia, weakness, elevated CPK, rhabdomyolysis, hypotension, dyspnea, chest tightness, urticaria, erythema, facial edema, lymphangiectasia, gastrointestinal symptoms, abdominal distension, dyspepsia, mild abdominal pain, diarrhea, gastric discomfort, thirst, glossitis, depression, anxiety, headache, taste disorder, dizziness, drowsiness, sensory disturbances, sensation decrease, decreased attention, insomnia, elevated BUN, frequency of urination, visual disturbances, tinnitus, anaphylactic reaction, angioedema, systemic lupus erythematosus, elevated total cholesterol in the blood, elevated triglycerides, malaise, tongue discoloration, palpitations, edema, menstrual irregularities, paralysis, systemic disorders, fever, fatigue, weight loss, anaphylactic reaction, serum sickness-like reaction, blurred vision, decreased vision, hearing loss, auditory impairment, vasculitis, permanent loss of smell, hyposmia, drug rash, pancreatitis, rhabdomyolysis, influenza-like illness, elevated blood creatine phosphokinase

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air and moisture, ideally at room temperature between 1 degree and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness and prevent degradation.

Appearance and packaging

Appearance

White to almost off-white circular tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.